Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. - Wikidata - wikimedia - TriplyDB

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

http://www.wikidata.org/entity/Q37278365

about

Targeted therapies in sarcomas: challenging the challenge Pazopanib in the management of advanced soft tissue sarcomas Modeling human endothelial cell transformation in vascular neoplasias Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis Advances in sarcoma diagnostics and treatment Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin Pazopanib, a new therapy for metastatic soft tissue sarcoma Key roles for MYC, KIT and RET signaling in secondary angiosarcomas Systemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcoma Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)Optimizing biologically targeted clinical trials for neurofibromatosis.Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).The evolution of systemic therapy in sarcoma.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Comprehensive pharmacological profiling of neurofibromatosis cell lines.Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.Clinical management of secondary angiosarcoma after breast conservation therapy Unusual primary breast cancer - malignant peripheral nerve sheath tumor: a case report and review of the literature Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013.Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.Phase II studies in soft tissue sarcoma: time for reappraisal.New therapeutic targets in soft tissue sarcoma.Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma Combining targeted agents with modern radiotherapy in soft tissue sarcomas.Sarcomas of the heart as a difficult interdisciplinary problem Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma

P2860

Q21285014-0D132194-99A6-45C4-9F0A-17BF92FF11EC Q26746205-C1862BDB-DA54-4F6C-9BC3-D6AA9042B9DE Q26860203-094D410F-BD2E-4549-9C66-6BD7732FF816 Q27003304-F4BB831A-890D-4EC9-BD5F-34C98285D7C3 Q28069695-79AF962D-C6D6-4C0B-BFCC-2E1E7B0601E5 Q28076210-0B7819AE-477A-4979-A285-9ED3D730509A Q28087771-AA5F0230-AAFE-4ABB-9821-DF368AE503B9 Q28287163-349687C2-79CE-4DC6-87AB-EA6A48FE8421 Q28390442-0685511B-8495-427A-A95D-8B4483723D4A Q28485467-AA35E8CD-EB6B-4EB0-B937-EAAB871C3A10 Q28732214-3A99380C-BB4F-4ED4-9988-8459F855548E Q30438898-E15BEC4A-4CB0-4829-8865-AF0A2110D7A2 Q30620556-FF1067AA-00AD-49A2-9490-0BF70D504ADF Q30834078-5DCA9B41-D096-42F7-B81C-1F12C73AE9A5 Q31018689-CCF35BE1-ABF3-43F1-B933-32F1691B3C37 Q33274710-26259CC8-D548-4F41-BED4-173213EF219D Q33386535-7B5C9446-2E86-48D6-B50A-0487D80A44B9 Q33395853-9AB835EE-0518-4704-9D18-D46BD2750440 Q33404411-A3480A37-AAD1-4B2C-A254-6E39A5A78D82 Q33408668-42628138-D7E9-452F-B7B5-41446DC1BF1D Q33410972-FB0C35AB-CCB7-4202-A4BC-D912FDCC015B Q33418378-48FF72AE-6A43-4116-B0B0-A1D37203A87F Q33420695-5AC44541-7916-4707-90F6-3E76085D2D0F Q33438485-7D5B25A7-73C5-414D-AC8D-A10B4F8643B6 Q33622690-128C4A06-02FE-47EB-A4F1-8B458FCF50D1 Q33737662-9CB17BFB-0446-4319-8071-33FB202650D9 Q33751719-15917229-ED1B-49FC-AFBB-469757B3F13A Q33808614-833FE525-F76D-4041-9196-44A97B5BCC40 Q33826258-61DE49B0-738E-49CB-9500-C73694AADD44 Q34038664-FE2C41EB-894A-4572-8BE4-FDE3FFB6BA08 Q34129496-FF670AAF-9070-4B32-A77A-C61A3D95A1BD Q34143849-B7F92FD6-60EB-4115-9E11-443816D97B7F Q34267924-DC807CC0-4F34-4E62-8FF1-73C89C85870C Q34354781-65D7AEE5-894F-4C28-8760-1D426E641545 Q34396047-573CC48C-D8BD-4411-BBD1-933DA15365D0 Q34413647-7AE5BE99-CB96-483B-AF8D-3F5C7A76A8DB Q34443645-7A29E2A3-348B-40F0-BEB2-603DB8A6D58D Q34554398-61772FCE-F0C8-4A67-B232-A48978505997 Q34628840-3733D542-A76E-4DEB-B21A-BC300B8F5FC5 Q34629491-2296A8C5-C821-4876-9D0F-3B751A6F5E91

P2860

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

http://www.wikidata.org/entity/Q37278365

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@en

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@nl

type

label

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@en

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@nl

prefLabel

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@en

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

@nl

P1433

Q37278365-0EE46B0B-C144-4160-A4A7-1403C6D226C8

P1476

Q37278365-94BA9C06-F51D-4881-BC1F-ACA3323AEEDF

P2093

Q37278365-112516F1-8519-4B53-A216-1BEDDCF8507C

Q37278365-167691E2-77F8-4254-9810-0833E8E0BF98

Q37278365-17D0139C-E570-43B4-965C-58CE848621BD

Q37278365-20795E67-6ECB-43E2-A5DE-26EEFC321211

Q37278365-24795824-345F-478A-BE6D-9683D0CAE5BB

Q37278365-2BE86FD3-FE32-4895-843B-A0D7814DC8C6

Q37278365-4B873767-9960-408C-BFE7-4631C9E11BF1

Q37278365-79FBDB87-5D06-42DC-BA38-63C72A31F8FC

Q37278365-7F64D027-699F-491B-A021-AE8BFE34D397

Q37278365-90054806-E524-449C-A6CD-4BD296999EC0

P2860

Q37278365-07CC2418-BC6D-4C06-83DE-D67359AF1920

Q37278365-0800D11E-6249-49D0-8273-5D0235DA3763

Q37278365-080B3645-46F5-4DF7-93E5-640E224AC477

Q37278365-10D70023-4A45-4FE8-A981-2032DB14E297

Q37278365-18CB9A4E-AFC9-4AC3-9215-67470AD55C57

Q37278365-201972D2-9EBC-4FF8-9931-720026255A94

Q37278365-34FB47DD-8E8D-4DF9-AAE9-5EB7E0A00A44

Q37278365-44EDF635-0E3B-4518-B332-91F13581523E

Q37278365-463FE872-7670-4899-A1BB-A18B3FB47FB9

Q37278365-4C558C5B-EA55-4FF1-A6A7-AC097FBA7E8F

P304

Q37278365-31E99D15-5267-4A42-8106-E9839A9044AD

P31

Q37278365-C537E96D-C234-44F3-83CA-74D02F275AB9

P356

Q37278365-22FD9F37-735A-4D7C-9FB9-1D1A72F40405

P407

Q37278365-187D4BB8-0F8F-4426-8235-A764D3BE6C4D

P433

Q37278365-2372B79D-FDE7-477E-A5B4-41F8DAFC52C3

P478

Q37278365-8FC3E7EE-9861-4E65-A85F-F570A32B82C5

P50

Q37278365-35E6F861-1525-4F1C-A182-8C6084372A1C

P577

Q37278365-9ECF29EC-80EE-4767-8DED-F479BBF2AA2A

P698

Q37278365-CEDD89F7-A2F6-468C-B99B-CF23288FE1C8

P932

Q37278365-3C64D1A6-946D-4083-8F07-A58164CAC28A

P356

JCO.2008.20.4495

P1433

Journal of Clinical Oncology

P1476

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas

@en

P2093

Andrew S Kraft

http://www.w3.org/2001/XMLSchema#string

Anthony D Elias

http://www.w3.org/2001/XMLSchema#string

Bruce Brockstein

http://www.w3.org/2001/XMLSchema#string

Chris H Takimoto

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

David R D'Adamo

http://www.w3.org/2001/XMLSchema#string

Gary K Schwartz

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

Li-Xuan Qin

http://www.w3.org/2001/XMLSchema#string

Mark A Edgar

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

P304

3133-3140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.4495

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19451436

http://www.w3.org/2001/XMLSchema#string

P932

2716936

http://www.w3.org/2001/XMLSchema#string